Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Afatinib in Advanced Refractory Urothelial Cancer
NCT02122172 · University of Chicago · PHASE2 · terminated · last registry update 2025-04-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Unable to meet accrual goal after several years” | – | Registry record, University of Chicago |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGFR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-23Also stopped (terminated): National Cancer Institute (NCI), Alectinib + Brigatinib (NCT03737994)
- 2026-04-21Also stopped (terminated): Institut Paoli-Calmettes, BKM120 + lapatinib (NCT01589861)
- 2026-04-17Phase 3 first posted: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Nimotuzumab + Nimotuzumab, Benmelstobart (NCT07535567)
- 2026-03-17Results posted on the registry: National Cancer Institute (NCI), Bevacizumab + Osimertinib (NCT02971501)
- 2026-03-03Phase 3 first posted: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Bemcentinib + Nimotuzumab (NCT07445048)
- 2026-02-12Results posted on the registry: M.D. Anderson Cancer Center, Cyclophosphamide + Doxorubicin (NCT03101748)
- 2026-02-12Also stopped (terminated): M.D. Anderson Cancer Center, Cyclophosphamide + Doxorubicin (NCT03101748)
- 2026-02-10Results posted on the registry: AstraZeneca, Osimertinib + Savolitinib (NCT03778229)
- 2026-02-04Results posted on the registry: Yale University, cetuximab + afatinib (NCT02979977)
- 2026-02-02Results posted on the registry: Janssen Research & Development, LLC, Lazertinib + Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) (NCT05388669)
- 2026-01-29Phase 3 first posted: CSPC Megalith Biopharmaceutical Co.,Ltd., SYS6010 + Osimertinib (NCT07376382)
- 2026-01-22Also stopped (terminated): Dana-Farber Cancer Institute, Neratinib + Fulvestrant (NCT03289039)
- 2026-01-22Results posted on the registry: University of Alabama at Birmingham, Combination of Veliparib + Lapatinib (NCT02158507)
- 2026-01-13Results posted on the registry: AstraZeneca, Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin + Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin (NCT04765059)
- 2026-01-12Phase 3 first posted: Shandong Cancer Hospital and Institute, Nimotuzumab (NCT07333274)
- 2026-01-12Results posted on the registry: Boehringer Ingelheim, Methotrexate + Afatinib (NCT01856478)
- 2025-11-19Also stopped (withdrawn): West China Hospital, Tislelizumab + Afatinib (NCT06804850)
- 2025-10-31Results posted on the registry: European Organisation for Research and Treatment of Cancer - EORTC, Osimertinib + Gefitinib (NCT02856893)
- 2025-10-20Results posted on the registry: Janssen Research & Development, LLC, Dexamethasone + Montelukast (NCT05663866)
- 2025-10-15Results posted on the registry: AstraZeneca, osimertinib (NCT05215951)
- 2025-10-15Also stopped (terminated): AstraZeneca, osimertinib (NCT05215951)
- 2025-10-09Results posted on the registry: University of Southern California, docetaxel + lapatinib ditosylate (NCT01382706)
- 2025-10-09Also stopped (terminated): University of Southern California, docetaxel + lapatinib ditosylate (NCT01382706)
- 2025-09-22Phase 3 first posted: ArriVent BioPharma, Inc., Firmonertinib + EGFR-TKI inhibitor based on investigator's choice (NCT07185997)
- 2025-09-19Phase 3 first posted: Suzhou Suncadia Biopharmaceuticals Co., Ltd., SHR-A2009 ; Aumolertinib + Aumolertinib (NCT07183189)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision